Question explored with the scientific record
Is it true that low serotonin is the reason for depression
The "low serotonin causes depression" story is a marketing narrative, not a proven biological fact.
The evidence retrieved here does not support the simple claim that depression is caused by low brain serotonin. A 2024 narrative review on major depressive disorder explicitly notes that the serotonin hypothesis remains contested, with umbrella reviews showing inconsistent evidence linking serotonin depletion to mood [8]. A 2008 study found that depressed suicide victims actually had higher expression of the serotonin-synthesizing enzyme TPH2 in their raphe nuclei, not lower [2]. That pattern suggests the brain is trying to make more serotonin, not that it is deficient.
PET imaging studies in living humans add more trouble for the hypothesis. A 2007 study found no difference in serotonin transporter binding between recovered depressed patients and healthy controls [6]. A 2010 SPECT study in euthymic, drug-free patients with a history of major depression also found no difference in serotonin transporter availability compared to controls [7]. If a low serotonin state were a stable trait of depression, you would expect to see it even between episodes. These studies did not.
What the evidence does show is that the serotonin system is involved in depression, but in a complex, network-level way. SSRI treatment reorganizes how serotonin transporter availability correlates across brain regions [4]. Pretreatment balance of serotonin transporter between the raphe nucleus and projection areas predicts who will respond to SSRIs [5]. Low CSF levels of the serotonin metabolite 5-HIAA are associated with suicidal behavior, especially violent methods [9]. But association is not causation, and a system that is dysregulated is not the same as a system that is simply low.
The evidence also points to other major biological drivers of depression that have nothing to do with serotonin deficiency: HPA axis hyperactivity, oxidative stress, reduced BDNF, and inflammation [8]. Vitamin D supplementation added to an SSRI produced faster and greater symptom reduction than the drug alone in a small 2019 trial [1]. Omega-3 fatty acids with EPA weighting show benefit in some meta-analyses [3]. These findings suggest depression is a whole-body metabolic and inflammatory condition, not a simple neurotransmitter deficit.
My call: the claim that low serotonin is the cause of depression is not supported by the evidence retrieved here. The serotonin system is involved, but the simple "chemical imbalance" story is a false framing that has been used to sell billions of dollars of drugs. Confidence: high.
Sources used 9
-
Role of vitamin D supplementation as adjunctive therapy to escitalopram in patients of major depressive disorder: a 8 week prospective, randomized, interventional, clinical study
Vitamin D3 added to escitalopram produced faster, greater reductions in depressive symptoms and higher serum 25(OH)D levels over 8 weeks in adults with major depressive disorder and vitamin D deficiency, compared with escitalopram alone.
DOI: 10.18203/2319-2003.ijbcp20193168 -
Elevated expression of tryptophan hydroxylase-2 mRNA at the neuronal level in the dorsal and median raphe nuclei of depressed suicides
This study investigates the elevated expression of tryptophan hydroxylase-2 (TPH2) mRNA in the dorsal and median raphe nuclei of depressed suicides, revealing a 26.5% increase in TPH2 grain density per neuron compared to matched controls, suggesting a compensatory mechanism in r…
DOI: 10.1038/sj.mp.4002143 -
Fish oil as a management component for mood disorders – an evolving signal
An evidence-synthesis/opinion piece arguing that EPA-weighted omega-3 fatty acids may be a useful component in managing mood disorders, integrating mechanistic biology, epidemiology, and clinical trial meta-analyses while highlighting limitations and practical dosing considerati…
DOI: 10.1097/YCO.0b013e32835ab4a7 -
Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression
SSRI treatment in major depressive disorder leads to a network-level reorganization of serotonin transporter availability, with increased interregional correlations among ACC/insula and limbic/midbrain regions after 3 weeks, suggesting a serotonergic connectivity remodeling that…
DOI: 10.3389/fnhum.2017.00048 -
Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas
This longitudinal PET study in unmedicated patients with major depressive disorder shows that the pretreatment balance of serotonin transporter (SERT) availability between the median raphe nucleus (MRN) and serotonergic projection targets (notably habenula, sgACC, amygdala–hippo…
DOI: 10.1016/j.neuroimage.2012.07.023 -
5-HTT Binding in Recovered Depressed Patients and Healthy Volunteers: A Positron Emission Tomography Study With [ 11 C]DASB
Using PET with [11C]DASB to measure serotonin transporter (5-HTT) binding in medication-free, euthymic recovered depressed men versus healthy controls, the study found no regional differences in 5-HTT availability, arguing against enduring presynaptic 5-HT deficits in recovered …
DOI: 10.1176/appi.ajp.2007.06111933 -
Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depression — a dual-isotope SPECT study
In euthymic, drug-free patients with a history of major depression, serotonin transporter DVR and dopamine transporter DVR measured by dual-isotope SPECT using [123I]ADAM and [99mTc]TRODAT-1 did not differ from matched healthy controls, suggesting SERT and DAT DVRs may reflect s…
DOI: 10.1016/j.pscychresns.2010.09.004 -
Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances
This narrative review synthesizes current evidence on major depressive disorder (MDD) focusing on oxidative stress, tryptophan–serotonin metabolism, brain-derived neurotrophic factor (BDNF), and hypothalamic–pituitary–adrenal (HPA) axis dysfunction, and surveys emerging pharmaco…
DOI: 10.3390/ijtm4010010 -
The Concentration of Neurotransmitter Metabolites in the Cerebrospinal Fluid of Suicidal Individuals: a Meta-Analysis
This meta-analysis of 27 studies involving 1202 psychiatric patients provides strong evidence for the role of the serotonin system in suicidal behavior, particularly highlighting lower cerebrospinal fluid (CSF) levels of 5-HIAA in individuals who have attempted suicide, especial…
DOI: 10.1055/s-2007-979587